Description

Rami Sandoz (ramipril) tablets 2.5 mg. №30

Ingredients

Active ingredient: Ramipril 2.5 mg
Other ingredients: lactose monohydrate, pregelatinized starch, croscarmellose sodium, and magnesium stearate.

Dosage

Dosage: The usual starting dose is 2.5 mg once daily. Dosage may be adjusted according to the individual patient’s response.

Indications

Indications: Rami Sandoz is indicated for the treatment of hypertension, heart failure post-myocardial infarction, and diabetic nephropathy.

Contraindications

Contraindications: Do not use Rami Sandoz if you are allergic to ramipril or any other ACE inhibitor. Avoid use during pregnancy as it can cause harm to the fetus.

Directions

Directions: Take Rami Sandoz exactly as prescribed by your healthcare provider. Swallow the tablet whole with a glass of water. It can be taken with or without food.

Scientific Evidence

Scientific Evidence: Several studies have demonstrated the efficacy of ramipril in reducing cardiovascular events and mortality in patients with cardiovascular risk factors. A study by Yusuf et al. (2000) showed a significant reduction in the risk of myocardial infarction, stroke, and cardiovascular death with ramipril therapy.

Additional Information

Additional Information: It is important to monitor blood pressure regularly while taking Rami Sandoz. Inform your doctor of any side effects such as dizziness, cough, or swelling of the face, lips, or throat.

Pharmacological Effects: Ramipril is an ACE inhibitor that works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. By inhibiting this process, ramipril helps dilate blood vessels, reduce blood pressure, and improve cardiac function.

Clinical Trials: Clinical trials have shown that ramipril is effective in reducing the risk of cardiovascular events in patients with high blood pressure, heart failure, and diabetes. The HOPE study demonstrated a 22% reduction in the composite endpoint of cardiovascular death, myocardial infarction, and stroke with ramipril therapy compared to placebo.